Drugs for the Heart E-Book

Bernard J. Gersh, Lionel H. Opie

Description

The new edition of this market-leading cardiac drug resource equips you with the latest advances in cardiovascular pharmacology, one of the most rapidly changing areas of medicine. It not only offers in-depth information on all of the drug classes used to treat heart disease, but also covers new drug classes, drug use for single and multiple problem management, and more. Dynamic full-color drawings illustrate key pharmacological and physiological actions, and a user-friendly organization directs you to the information you need. An increased emphasis on the practical use of drugs saves you valuable time in researching relevant information.

• Features the practice-proven experience of two well-known editors who represent the best possible combination of clinical and research expertise in cardiovascular therapeutics.
• Offers easy-to-access, useful information on when to use each drug—and for what conditions—in a chapter entitled “Which Drug for Which Disease.
• Discusses the management of single diseases and multiple comorbidities.
• Summarizes each drug class at the end of chapters to expedite reference.

• Incorporates all-new drugs, preparations, and clinical trial data in each chapter, equipping you to make the most up-to-date, informed clinical decisions.
• Offers expanded coverage of comorbid diseases through new chapters on metabolic syndrome, hyperglycemia, and diabetes.
• Features an increased emphasis on the practical use of drugs through highlighted sections and key illustrations, saving you time in searching for relevant information.
• Presents the work of several new contributors who represent a broad international perspective to equip you with a global view of cardiovascular pharmacology.

Informations

• Publié par: Saunders
• Date de parution: 01 décembre 2011
• Nombre de lectures: 0
• EAN13: 9781455740895
• Langue: English
• Poids de l'ouvrage: 5 Mo

Extrait

DRUGS FOR THE HEART
Seventh Edition

Lionel H. Opie, MD, DPhil, DSc, FRCP
Director, Hatter Institute for Cardiology Research
Professor Emeritus, Department of Medicine
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

CO-EDITOR
Bernard J. Gersh, MBChB, DPhil, FACC
Professor of Medicine, Cardiovascular Division, Mayo Clinic, Rochester, Minnesota

FOREWORD BY
Eugene Braunwald, MD
ORIGINAL ARTWORK BY
Jeannie Walker
SAUNDERS
Front Matter

DRUGS FOR THE HEART
7TH EDITION
Lionel H. Opie, MD, DPhil, DSc, FRCP
Director, Hatter Institute for Cardiology Research
Professor Emeritus, Department of Medicine
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
CO-EDITOR
Bernard J. Gersh, MBChB, DPhil, FACC
Professor of Medicine
Cardiovascular Division
Mayo Clinic
Rochester, Minnesota
FOREWORD BY
Eugene Braunwald, MD
ORIGINAL ARTWORK BY
Jeannie Walker
Copyright
SAUNDERS ELSEVIER
1600 John F. Kennedy Blvd.
Ste 1800
Philadelphia, PA 19103-2899
DRUGS FOR THE HEART
ISBN: 978-1-4160-6158-8
Copyright © 2009 by Saunders, an imprint of Elsevier Inc.
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Rights Department: phone: [phone] (US) or ([phone] (UK); fax: [phone]; e-mail: [e-mail] . You may also complete your request on-line via the Elsevier website at http://www.elsevier.com/permissions .


Notice
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on their own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors assumes any liability for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this book.
The Publisher
Previous editions copyrighted 2005, 2001, 1995, 1991, 1987, 1984 by Saunders, an imprint of Elsevier Inc.
Mayo drawings, photographs, and illustrations © 2009 by Mayo Foundation for Medical Education and Research.
Illustrations copyright © 2008, 2005, 2004, 2001, 1995, 1991, 1987, 1984 by Lionel H. Opie.
Dr. Opie retains ownership of the illustrations used in this Work. Dr. Opie should retain copyright ©.
Adapted from Drugs and the Heart , copyright © 1980 by Lionel H. Opie.
Library of Congress Cataloging-in-Publication Data
Opie, Lionel H.
Drugs for the heart/Lionel H. Opie, Bernard J. Gersh.—7th ed. p.; cm.
Includes bibliographical references.
ISBN 978-1-4160-6158-8
1. Cardiovascular agents. I. Gersh, Bernard J. II. Title.
[DNLM: 1. Cardiovascular Agents—pharmacology. 2. Cardiovascular Agents—therapeutic use. 3. Cardiovascular Diseases—drug therapy. QV 150 O61d 2009]
RM345.D784 2009
615′.71—dc22
2008011020
Executive Publisher: Natasha Andjelkovic
Editorial Assistant: Isabel Trudeau
Design Direction: Ellen Zanolle
Printed in China
Last digit is the print number: 9 8 7 6 5 4 3 2 1
Contributors

John P. DiMarco, MD, PhD, Professor of Medicine, Cardiovascular Division, Director, Clinical Electrophysiology Laboratory, University of Virginia Health Sciences, Charlottesville, Virginia

Keith A.A. Fox, BSc, MBChB, FRCP, FESC, FMedSci, Duke of Edinburgh British Heart Foundation Professor of Cardiology, Consultant Cardiologist, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom

Antonio M. Gotto, Jr., MD, DPhil, The Stephen and Suzanne Weiss Dean and Professor of Medicine, Weill Medical College of Cornell University, New York, New York, Provost for Medical Affairs, Cornell University, Ithaca, New York

John D. Horowitz, MBBS, PhD, FRACP, Professor of Cardiology, Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia

Norman M. Kaplan, MD, Clinical Professor of Medicine, Hypertension Division, University of Texas Southwestern Medical School, Dallas, Texas

John M. Miles, MD, Professor of Medicine, Endocrine Research Unit, Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota

Jessica J.S. Opie, MBChB (Hons), MRCP (UK), FRCPA (Haem), Consultant Laboratory Haematologist, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa

Marc A. Pfeffer, MD, PhD, Victor Dzau Professor of Medicine, Harvard Medical School, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

Philip A. Poole-Wilson, MD, FRCP, Professor, Department of Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, United Kingdom

Sidney C. Smith, Jr., MD, FACC, FAHA, FESC, Professor of Medicine, Director, Center for Cardiovascular Science and Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Harvey White, DSc, Honorary Clinical Professor, Department of Medicine, Auckland University, Director of Coronary Care and Cardiovascular Research, Green Lane Cardiology, Auckland City Hospital, Auckland, New Zealand
Foreword
Cardiovascular disease is destined to become an even more important cause of morbidity and mortality as the population of the so-called developing world ages and the epidemic of ischemic heart disease in more affluent and more obese persons in the developing world sets in. Fortunately, an ever growing array of drugs acting on the cardiovascular system continues to become available. These agents are more efficacious and better tolerated than their predecessors not only in the management of established disease, but also increasingly in prevention. However, both trainees and practitioners of medicine and cardiology have ever increasing difficulty in deciding how to choose the proper therapies for their patients. Professors Opie and Gersh’s book provides a rational approach to help with these important decisions. Drugs for the Heart is a concise yet complete presentation of cardiac pharmacology and therapeutics. It presents, in a very readable and eminently understandable fashion, an extraordinary amount of important information on the effects of drugs on the heart and circulation. The editors and the talented authors they have enlisted have the unique ability to explain in a straightforward manner the mechanism of action of drugs without oversimplification. This book also summarizes the results of important clinical trials that have shaped regulatory approval and practice guidelines. Finally, it provides important practical information to the clinician.
The seventh edition of this now well-established and admired book builds on the strengths of its predecessors. The excellent explanatory diagrams (an Opie trademark) are even better and more numerous than in previous editions, while the text and references in this rapidly moving field are as fresh as this week’s journals. For example, since the publication of the sixth edition the landscape of care of the patient with acute coronary syndromes has changed considerably. Among the many new drugs described in this edition include: nebivolol, a new beta blocker that generates nitric oxide; new anti-anginals that block the late inward sodium current (ranolazine), or slow the heart rate (ivabradine); renin blockers in the treatment of hypertension; vaptans in the management of acute heart failure; and anti-arrhythmic agents such as vernalakant for the treatment of atrial fibrillation. Among antithrombotics are bivalirudin, a direct thrombin inhibitor, fondaparinux, a factor Xa inhibitor; the new antiplatelet drug, prasugrel; ezetimibe, an inhibitor of cholesterol absorption; as well as glitazones and incretin enhancers in the management of the metabolic syndrome and diabetes.
I strongly recommend this concise volume which will be of enormous value and interest to all—specialists, generalists, clinicians, trainees at all levels, teachers and scientists—who wish to gain a clear understanding of contemporary cardiovascular therapeutics and apply this information most effectively in the care of patients with cardiovascular disease.

Eugene Braunwald, MD, Distinguished Hersey Professor of Medicine, Harvard Medical School, Boston, Massachusetts
The Lancet Editorial, 1980
(An Editorial from The Lancet, March 29, 1980, to introduce a series of articles on Drugs and the Heart)
Cardiovascular times are achanging. After a mere ten years’ repose the medical Rip van Winkle would be thoroughly bewildered. For instance, there has been a big switch in attitudes to the failing heart. What would he make of those soft voices which now preach unloading or “afterlo